Press Releases Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:24 2024-07-08 am EDT			5-day change	1st Jan Change
27.15 ^HKD	+0.18%		+6.26%	-0.55%

Jul. 04	Ascentage Grants Takeda Exclusive Option for Licensing of Blood Cancer Drug	MT
Jun. 21	Ascentage Pharma Group Completes $75 Million Share Subscription Deal with Takeda International	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascentage Pharma - Olverembatinib Approved for Commercialization in Macau China	Jul. 08	AQ
Olverembatinib Approved for Commercialization in Macau China	Jul. 07	PR
Ascentage Pharma Received US$100 Million Option Payment from Takeda	Jul. 03	PR
Ascentage Pharma Announces Closing of US$75 Million Equity Investment by Takeda	Jun. 20	PR
Ascentage Pharma Signs Option Agreement with Takeda to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	Jun. 14	PR
EHA 2024 \| Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress	May. 15	PR
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	May. 14	AQ
Ascentage Pharma Announces 2023 Annual Results	Mar. 28	AQ
Global Registrational Phase III Study of Olverembatinib (HQP1351) Cleared by FDA	Feb. 13	PR
Ascentage Pharma to Present at 42nd J.P. Morgan Healthcare Conference	Jan. 01	PR
Live from ASH 2023, Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR	Dec. 12	AQ
Live from ASH 2023, Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib	Dec. 12	AQ
Live from ASH 2023, Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73.3%	Dec. 12	AQ
Small Lymphocytic Lymphoma Pipeline, FDA Approvals, Clinical Trials Developments, Companies 2023 \| Loxo Oncology, Chia Tai Tianqing Pharmaceutical Group, Iovance Biotherapeutics, and others.	Dec. 05	AQ
Live from ESMO 2023 \| Oral Report Featuring Latest Data of Pelcitoclax (APG-1252) Combined with Osimertinib Demonstrates Potential as a New Treatment Option for TP53-and EGFR-Mutant NSCLC	23-10-23	PR
Ascentage Pharma - First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naive Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	23-10-18	AQ
First Patient Dosed in the Registrational Phase III Study of Olverembatinib in Treatment-Naïve Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)	23-10-17	PR
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax in Previously Treated Patients with CLL/SLL	23-08-07	AQ
Ascentage Pharma Received Clearance from U.S. FDA to Proceed with Global Registrational Phase III Clinical Trial for Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL	23-08-06	PR
ESMO 2023 \| Ascentage Pharma to Present Results from Two Clinical Studies, including One Oral Presentation, at 2023 ESMO Congress	23-08-02	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Press Releases

Filters